203 related articles for article (PubMed ID: 22621282)
21. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
van der Kraan AG; Chai RC; Singh PP; Lang BJ; Xu J; Gillespie MT; Price JT; Quinn JM
Biochem J; 2013 Apr; 451(2):235-44. PubMed ID: 23379601
[TBL] [Abstract][Full Text] [Related]
22. Hsp90 Inhibitor Attenuates the Development of Pathophysiological Cardiac Fibrosis in Mouse Hypertrophy via Suppression of the Calcineurin-NFAT and c-Raf-Erk Pathways.
Marunouchi T; Nakashima M; Ebitani S; Umezu S; Karasawa K; Yano E; Tanonaka K
J Cardiovasc Pharmacol; 2021 Jun; 77(6):822-829. PubMed ID: 34016843
[TBL] [Abstract][Full Text] [Related]
23. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.
Beloueche-Babari M; Arunan V; Jackson LE; Perusinghe N; Sharp SY; Workman P; Leach MO
Oncotarget; 2010 Jul; 1(3):185-97. PubMed ID: 21037799
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
25. Heat Shock Protein 90 Inhibitor Decreases Collagen Synthesis of Keloid Fibroblasts and Attenuates the Extracellular Matrix on the Keloid Spheroid Model.
Lee WJ; Lee JH; Ahn HM; Song SY; Kim YO; Lew DH; Yun CO
Plast Reconstr Surg; 2015 Sep; 136(3):328e-337e. PubMed ID: 26313837
[TBL] [Abstract][Full Text] [Related]
26. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
27. Inhibitors of the HSP90 molecular chaperone: current status.
Sharp S; Workman P
Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
[TBL] [Abstract][Full Text] [Related]
28. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
[TBL] [Abstract][Full Text] [Related]
29. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Gaspar N; Sharp SY; Pacey S; Jones C; Walton M; Vassal G; Eccles S; Pearson A; Workman P
Cancer Res; 2009 Mar; 69(5):1966-75. PubMed ID: 19244114
[TBL] [Abstract][Full Text] [Related]
30. Molecular stress-inducing compounds increase osteoclast formation in a heat shock factor 1 protein-dependent manner.
Chai RC; Kouspou MM; Lang BJ; Nguyen CH; van der Kraan AG; Vieusseux JL; Lim RC; Gillespie MT; Benjamin IJ; Quinn JM; Price JT
J Biol Chem; 2014 May; 289(19):13602-14. PubMed ID: 24692538
[TBL] [Abstract][Full Text] [Related]
31. The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2015 Apr; 48(3):886-93. PubMed ID: 25096912
[TBL] [Abstract][Full Text] [Related]
32. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
Burger AM; Fiebig HH; Stinson SF; Sausville EA
Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic effects of radiolabeled 17-allylamino-17-demethoxygeldanamycin on human H460 nonsmall-cell lung carcinoma xenografts in mice.
Sun J; Liu L; Jiang X; Chen D; Huang Y
Cancer Biother Radiopharm; 2010 Apr; 25(2):155-64. PubMed ID: 20423228
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.
Sain N; Krishnan B; Ormerod MG; De Rienzo A; Liu WM; Kaye SB; Workman P; Jackman AL
Mol Cancer Ther; 2006 May; 5(5):1197-208. PubMed ID: 16731752
[TBL] [Abstract][Full Text] [Related]
35. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.
Giubellino A; Sourbier C; Lee MJ; Scroggins B; Bullova P; Landau M; Ying W; Neckers L; Trepel JB; Pacak K
PLoS One; 2013; 8(2):e56083. PubMed ID: 23457505
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
Solit DB; Osman I; Polsky D; Panageas KS; Daud A; Goydos JS; Teitcher J; Wolchok JD; Germino FJ; Krown SE; Coit D; Rosen N; Chapman PB
Clin Cancer Res; 2008 Dec; 14(24):8302-7. PubMed ID: 19088048
[TBL] [Abstract][Full Text] [Related]
37. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.
Cervantes-Gomez F; Nimmanapalli R; Gandhi V
J Pharmacol Exp Ther; 2011 Nov; 339(2):545-54. PubMed ID: 21821695
[TBL] [Abstract][Full Text] [Related]
38. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
Wu X; Wanders A; Wardega P; Tinge B; Gedda L; Bergstrom S; Sooman L; Gullbo J; Bergqvist M; Hesselius P; Lennartsson J; Ekman S
Br J Cancer; 2009 Jan; 100(2):334-43. PubMed ID: 19142186
[TBL] [Abstract][Full Text] [Related]
39. Heat shock protein 90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation.
Hughes D; Guttenplan JB; Marcus CB; Subbaramaiah K; Dannenberg AJ
Cancer Prev Res (Phila); 2008 Nov; 1(6):485-93. PubMed ID: 19138996
[TBL] [Abstract][Full Text] [Related]
40. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]